ProShares Ultra Nasdaq Biotechnology (BIB)
48.20
-0.75
(-1.53%)
USD |
NASDAQ |
Apr 18, 16:00
48.20
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.95% | -0.00% | 78.32M | 44030.13 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 0.16% | 23.00% | -8.056M | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Miscellaneous |
| Broad Category | Miscellaneous |
| Category Name | Trading--Leveraged Equity |
| Category Index | S&P 500 TR USD |
| Global Category Name | Trading Tools |
| YCharts Categorization | Other |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | ProShares |
| Prospectus Benchmark Index | |
| NASDAQ Biotechnology TR USD | 200.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Michael Neches | 10.51 yrs |
| Tarak Davé | 5.93 yrs |
Performance Versus Category
As of April 17, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of April 17, 2024.
Basic Info
| Investment Strategy | |
| The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Miscellaneous |
| Broad Category | Miscellaneous |
| Category Name | Trading--Leveraged Equity |
| Category Index | S&P 500 TR USD |
| Global Category Name | Trading Tools |
| YCharts Categorization | Other |
| YCharts Benchmark | S&P 500 Total Return (^SPXTR) |
| Prospectus Objective | Specialty - Technology |
| Fund Owner Firm Name | ProShares |
| Prospectus Benchmark Index | |
| NASDAQ Biotechnology TR USD | 200.0% |
| Broad Asset Class Benchmark Index | |
| ^SPXTR | 100.0% |
| Manager Tenure | |
| Michael Neches | 10.51 yrs |
| Tarak Davé | 5.93 yrs |